Bovine lactoferrin suppresses the cathepsin-dependent pathway of SARS-CoV-2 entry in vitro
Severe acute respiratory coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The frequent appearance of variants requires adjunct strategies to combat SARS-CoV-2 infections. Lactoferrin, a naturally occurring glycoprotein, exhibits promising antiviral properties. Here, we investig...
Saved in:
| Published in | International dairy journal Vol. 148; p. 105805 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
01.01.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Severe acute respiratory coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The frequent appearance of variants requires adjunct strategies to combat SARS-CoV-2 infections. Lactoferrin, a naturally occurring glycoprotein, exhibits promising antiviral properties. Here, we investigated the efficacy of bovine LF (bLF) against SARS-CoV-2 infection. SARS-CoV-2 pseudoviruses bearing the original Wuhan (wild-type), D614G mutant, or Omicron variant spike proteins were used to examine the effects of bLF on viral entry into host cells. We found that although bLF did not suppress entry of wild-type pseudoviruses into cells expressing both human angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), it did suppress entry of Omicron pseudoviruses into the cells. The results of this in vitro study highlight the spike protein-dependent effects of bLF on suppression of pseudovirus entry into host cells. Future clinical trials investigating the efficacy of bLF against SARS-CoV-2 infection should consider the differential impact of virus variants. |
|---|---|
| AbstractList | Severe acute respiratory coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The frequent appearance of variants requires adjunct strategies to combat SARS-CoV-2 infections. Lactoferrin, a naturally occurring glycoprotein, exhibits promising antiviral properties. Here, we investigated the efficacy of bovine LF (bLF) against SARS-CoV-2 infection. SARS-CoV-2 pseudoviruses bearing the original Wuhan (wild-type), D614G mutant, or Omicron variant spike proteins were used to examine the effects of bLF on viral entry into host cells. We found that although bLF did not suppress entry of wild-type pseudoviruses into cells expressing both human angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), it did suppress entry of Omicron pseudoviruses into the cells. The results of this in vitro study highlight the spike protein-dependent effects of bLF on suppression of pseudovirus entry into host cells. Future clinical trials investigating the efficacy of bLF against SARS-CoV-2 infection should consider the differential impact of virus variants. |
| ArticleNumber | 105805 |
| Author | Yusa, Junko Maeda, Toyonobu Shimada, Takahisa Hirose, Kimiharu Kobayashi-Sakamoto, Michiyo Kato, Yasumasa Tani, Hideki |
| Author_xml | – sequence: 1 givenname: Michiyo orcidid: 0000-0001-7472-2565 surname: Kobayashi-Sakamoto fullname: Kobayashi-Sakamoto, Michiyo – sequence: 2 givenname: Toyonobu surname: Maeda fullname: Maeda, Toyonobu – sequence: 3 givenname: Junko surname: Yusa fullname: Yusa, Junko – sequence: 4 givenname: Takahisa surname: Shimada fullname: Shimada, Takahisa – sequence: 5 givenname: Hideki surname: Tani fullname: Tani, Hideki – sequence: 6 givenname: Yasumasa surname: Kato fullname: Kato, Yasumasa – sequence: 7 givenname: Kimiharu surname: Hirose fullname: Hirose, Kimiharu |
| BookMark | eNqFkM1KAzEQx3OoYFt9BCFHL1uTTbIfeKrFLygIVr14CGk6iynbZE3Syr6Nz-KTmdKevAjDDPOf-Q_Mb4QG1llA6IKSCSW0uFpPzEoZ368nOclZ0kRFxAANSS2qrKh5cYpGIawJoSVh9RC937idsYBbpaNrwHtjcdh2nYcQIOD4AVirlLtgbLaCDuwKbMRd0r5Uj12DF9PnRTZzb1mO08T32Nif752J3p2hk0a1Ac6PdYxe725fZg_Z_On-cTadZ5oLETMoQFBeAVHAdFUTzmnBGVlqQpioKs75MrUNFwUFUja1LvOK6bLQUKf5krAxujzc7bz73EKIcmOChrZVFtw2SEZFCp4QpFVxWNXeheChkZ03G-V7SYncA5RreQQo9wDlAWDyXf_xaRNVNC59rEz7j_sXPy5-jA |
| CitedBy_id | crossref_primary_10_3389_fimmu_2024_1402135 crossref_primary_10_1016_j_jff_2024_106237 crossref_primary_10_3390_nu16183073 |
| Cites_doi | 10.1016/j.intimp.2021.107571 10.4062/biomolther.2020.201 10.1371/journal.ppat.1009500 10.1016/S0006-291X(03)00917-3 10.1038/s41598-023-35915-w 10.1016/j.cell.2020.02.052 10.1016/j.jiac.2014.08.003 10.3390/nu13020328 10.1016/j.idairyj.2022.105488 10.3390/nu14245274 10.1371/journal.ppat.1009013 10.1016/j.jtbi.2023.111568 10.15252/embj.2021108944 10.1139/bcb-2021-0342 10.3389/fviro.2022.849936 10.1038/d41586-021-02039-y 10.15252/embj.2020106765 10.1002/rmv.2381 10.1002/jmv.27282 10.20965/jdr.2023.p0027 10.1038/s41423-021-00836-z 10.15252/embj.2021107821 10.3390/nu15051285 10.1016/S0140-6736(20)30183-5 10.1007/s00430-022-00760-7 10.1007/s10534-022-00477-3 10.1038/d41586-020-02379-1 10.1016/j.crvi.2014.08.003 10.1371/journal.pone.0023710 10.1186/s12985-021-01490-7 10.3390/jcm10184276 10.1016/j.csbj.2021.05.002 10.1038/s41586-022-04479-6 10.1038/s41586-022-04474-x 10.1016/S0168-1702(99)00121-5 10.1080/22221751.2021.1888660 10.1128/JVI.01933-08 10.1016/bs.aivir.2016.08.004 10.1016/j.vaccine.2023.02.068 10.1099/vir.0.80955-0 10.3390/medicina57080842 10.1080/19420862.2022.2072455 10.3390/ijerph182010985 10.1016/j.cell.2020.09.032 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION 7S9 L.6 |
| DOI | 10.1016/j.idairyj.2023.105805 |
| DatabaseName | CrossRef AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Agriculture |
| ExternalDocumentID | 10_1016_j_idairyj_2023_105805 |
| GroupedDBID | --K --M .~1 0R~ 1B1 1RT 1~. 1~5 29J 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALCJ AALRI AAOAW AAQFI AAQXK AATLK AATTM AAXKI AAXUO AAYWO AAYXX ABBQC ABFNM ABFRF ABGRD ABJNI ABKYH ABMAC ABMZM ABRWV ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACMHX ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADQTV ADSLC ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEQOU AEUPX AEXOQ AFJKZ AFPUW AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRNS AGUBO AGWPP AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CITATION CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLV HVGLF HZ~ IHE J1W K-O KOM LW9 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAB SDF SDG SES SEW SNL SPCBC SSA SSH SSZ T5K WUQ Y6R ~G- ~KM 7S9 EFKBS L.6 |
| ID | FETCH-LOGICAL-c455t-e6e5148e0ae3c8904416430bc003588444b430f4561e07f9c7283c76ce9358b03 |
| ISSN | 0958-6946 |
| IngestDate | Fri Aug 22 20:38:15 EDT 2025 Thu Apr 24 23:03:51 EDT 2025 Tue Jul 01 00:59:10 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c455t-e6e5148e0ae3c8904416430bc003588444b430f4561e07f9c7283c76ce9358b03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7472-2565 |
| OpenAccessLink | https://doi.org/10.1016/j.idairyj.2023.105805 |
| PQID | 3153154095 |
| PQPubID | 24069 |
| ParticipantIDs | proquest_miscellaneous_3153154095 crossref_primary_10_1016_j_idairyj_2023_105805 crossref_citationtrail_10_1016_j_idairyj_2023_105805 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-00 20240101 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-00 |
| PublicationDecade | 2020 |
| PublicationTitle | International dairy journal |
| PublicationYear | 2024 |
| References | Hu (10.1016/j.idairyj.2023.105805_bib11) 2021; 10 Itamochi (10.1016/j.idairyj.2023.105805_bib14) 2023; 41 Tang (10.1016/j.idairyj.2023.105805_bib43) 2021; 11 Bermejo-Jambrina (10.1016/j.idairyj.2023.105805_bib2) 2021; 40 Redwan (10.1016/j.idairyj.2023.105805_bib37) 2014; 337 Algahtani (10.1016/j.idairyj.2023.105805_bib1) 2021; 57 Kell (10.1016/j.idairyj.2023.105805_bib18) 2020; 1221 Tani (10.1016/j.idairyj.2023.105805_bib44) 2021; 18 Yazawa (10.1016/j.idairyj.2023.105805_bib47) 2023; 13 Lang (10.1016/j.idairyj.2023.105805_bib23) 2011; 6 Rosa (10.1016/j.idairyj.2023.105805_bib38) 2021; 10 Kobayashi-Sakamoto (10.1016/j.idairyj.2023.105805_bib20) 2022; 100 Laporte (10.1016/j.idairyj.2023.105805_bib24) 2021; 17 Patil (10.1016/j.idairyj.2023.105805_bib33) 2023; 137 Ohashi (10.1016/j.idairyj.2023.105805_bib30) 2003; 306 Campione (10.1016/j.idairyj.2023.105805_bib3) 2021; 18 Meng (10.1016/j.idairyj.2023.105805_bib27) 2022; 603 Padmanabhan (10.1016/j.idairyj.2023.105805_bib32) 2023; 572 Kawasuji (10.1016/j.idairyj.2023.105805_bib17) 2022; 94 Koch (10.1016/j.idairyj.2023.105805_bib22) 2021; 40 Ikeda (10.1016/j.idairyj.2023.105805_bib13) 2000; 66 Yurkovetskiy (10.1016/j.idairyj.2023.105805_bib48) 2020; 183 Fukushi (10.1016/j.idairyj.2023.105805_bib5) 2005; 86 Wakabayashi (10.1016/j.idairyj.2023.105805_bib45) 2014; 20 Einerhand (10.1016/j.idairyj.2023.105805_bib4) 2022; 14 Hewins (10.1016/j.idairyj.2023.105805_bib6) 2022; 2 Hoffmann (10.1016/j.idairyj.2023.105805_bib7) 2020; 181 Ozawa (10.1016/j.idairyj.2023.105805_bib31) 2022; 14 Mirabelli (10.1016/j.idairyj.2023.105805_bib28) 2021; 118 Matino (10.1016/j.idairyj.2023.105805_bib26) 2023; 15 Rajah (10.1016/j.idairyj.2023.105805_bib36) 2021; 40 Pišlar (10.1016/j.idairyj.2023.105805_bib35) 2020; 16 Kandeel (10.1016/j.idairyj.2023.105805_bib15) 2021; 29 Khatri (10.1016/j.idairyj.2023.105805_bib19) 2023; 212 Kobayashi-Sakamoto (10.1016/j.idairyj.2023.105805_bib21) 2023; 18 Shrestha (10.1016/j.idairyj.2023.105805_bib42) 2022; 32 Kawase (10.1016/j.idairyj.2023.105805_bib16) 2009; 83 Perlman (10.1016/j.idairyj.2023.105805_bib34) 2020; 584 Scudellari (10.1016/j.idairyj.2023.105805_bib41) 2021; 595 Salaris (10.1016/j.idairyj.2023.105805_bib39) 2021; 13 Hu (10.1016/j.idairyj.2023.105805_bib12) 2022; 19 Li (10.1016/j.idairyj.2023.105805_bib25) 2023; 120 Schuurs (10.1016/j.idairyj.2023.105805_bib40) 2021; 19 Navarro (10.1016/j.idairyj.2023.105805_bib29) 2023; 36 Huang (10.1016/j.idairyj.2023.105805_bib8) 2020; 395 Hulswit (10.1016/j.idairyj.2023.105805_bib10) 2016; 96 Yamada (10.1016/j.idairyj.2023.105805_bib46) 2022; 12 Hui (10.1016/j.idairyj.2023.105805_bib9) 2022; 603 Zimecki (10.1016/j.idairyj.2023.105805_bib49) 2021; 95 |
| References_xml | – volume: 95 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib49 article-title: The potential for lactoferrin to reduce SARS-CoV-2 induced cytokine storm publication-title: International Immunopharmacology doi: 10.1016/j.intimp.2021.107571 – volume: 29 start-page: 282 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib15 article-title: Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit publication-title: Biomolecular Therapy doi: 10.4062/biomolther.2020.201 – volume: 11 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib43 article-title: Characterization of SARS-CoV-2 variants N501Y.V1 and N501Y.V2 spike on viral infectivity publication-title: Frontiers in Cell Infection and Microbiology – volume: 17 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib24 article-title: The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways publication-title: PLoS Pathogens doi: 10.1371/journal.ppat.1009500 – volume: 306 start-page: 98 year: 2003 ident: 10.1016/j.idairyj.2023.105805_bib30 article-title: New functions of lactoferrin and β-casein in mammalian milk as cysteine protease inhibitors publication-title: Biochemical and Biophysical Research Communications doi: 10.1016/S0006-291X(03)00917-3 – volume: 13 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib47 article-title: Evaluation of SARS-CoV-2 isolation in cell culture from nasal/nasopharyngeal swabs or saliva specimens of patients with COVID-19 publication-title: Scientific Reports doi: 10.1038/s41598-023-35915-w – volume: 181 start-page: 271 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib7 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 20 start-page: 666 year: 2014 ident: 10.1016/j.idairyj.2023.105805_bib45 article-title: Lactoferrin for prevention of common viral infections publication-title: Journal of Infection and Chemotherapy doi: 10.1016/j.jiac.2014.08.003 – volume: 13 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib39 article-title: Protective effects of lactoferrin against SARS-CoV-2 infection in vitro publication-title: Nutrients doi: 10.3390/nu13020328 – volume: 137 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib33 article-title: Hydrolysis improves the inhibition efficacy of bovine lactoferrin against infection by SARS-CoV-2 pseudovirus publication-title: International Dairy Journal doi: 10.1016/j.idairyj.2022.105488 – volume: 14 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib4 article-title: Can lactoferrin, a natural mammalian milk protein, assist in the battle against COVID-19? publication-title: Nutrients doi: 10.3390/nu14245274 – volume: 16 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib35 article-title: The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors publication-title: PLoS Pathogens doi: 10.1371/journal.ppat.1009013 – volume: 572 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib32 article-title: Modelling how increased cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and cathepsin B/L inhibitors publication-title: Journal of Theoretical Biology doi: 10.1016/j.jtbi.2023.111568 – volume: 40 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib36 article-title: SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation publication-title: EMBO Journal doi: 10.15252/embj.2021108944 – volume: 100 start-page: 338 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib20 article-title: Bovine lactoferrin increases the poly(I:C)-induced antiviral response in vitro publication-title: Biochemistry and Cell Biology doi: 10.1139/bcb-2021-0342 – volume: 2 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib6 article-title: Alpha, beta, delta, omicron, and SARS-CoV-2 breakthrough cases: Defining immunological mechanisms for vaccine waning and vaccine-variant mismatch publication-title: Frontiers in Virology doi: 10.3389/fviro.2022.849936 – volume: 595 start-page: 640 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib41 article-title: How the coronavirus infects cells-and why Delta is so dangerous publication-title: Nature doi: 10.1038/d41586-021-02039-y – volume: 40 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib2 article-title: Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans publication-title: EMBO Journal doi: 10.15252/embj.2020106765 – volume: 32 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib42 article-title: Evolution of the SARS-CoV-2 omicron variants BA. 1 to BA. 5: Implications for immune escape and transmission publication-title: Reviews in Medical Virology doi: 10.1002/rmv.2381 – volume: 94 start-page: 147 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib17 article-title: SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19 publication-title: Journal of Medical Virology doi: 10.1002/jmv.27282 – volume: 18 start-page: 27 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib21 article-title: Lactoferrin as a possible preventive and therapeutic agent against SARS-CoV-2 infection publication-title: Journal of Disaster Research doi: 10.20965/jdr.2023.p0027 – volume: 19 start-page: 293 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib12 article-title: Increased immune escape of the new SARS-CoV-2 variant of concern Omicron publication-title: Cellular and Molecular Immunology doi: 10.1038/s41423-021-00836-z – volume: 40 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib22 article-title: TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells publication-title: EMBO Journal doi: 10.15252/embj.2021107821 – volume: 15 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib26 article-title: Effect of lactoferrin on clinical outcomes of hospitalized patients with COVID-19: The LAC randomized clinical trial publication-title: Nutrients doi: 10.3390/nu15051285 – volume: 118 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib28 article-title: Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19 publication-title: Proceedings of the National Academy of Sciences of the United States of America – volume: 395 start-page: 497 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib8 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 212 start-page: 103 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib19 article-title: Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity publication-title: Medical Microbiology and Immunology doi: 10.1007/s00430-022-00760-7 – volume: 36 start-page: 463 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib29 article-title: Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: A double-blinded randomized clinical trial (LF-COVID) publication-title: Biometals doi: 10.1007/s10534-022-00477-3 – volume: 584 start-page: 345 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib34 article-title: COVID-19 poses a riddle for the immune system publication-title: Nature doi: 10.1038/d41586-020-02379-1 – volume: 337 start-page: 581 year: 2014 ident: 10.1016/j.idairyj.2023.105805_bib37 article-title: Potential lactoferrin activity against pathogenic viruses publication-title: Comptes Rendus Biologies doi: 10.1016/j.crvi.2014.08.003 – volume: 6 year: 2011 ident: 10.1016/j.idairyj.2023.105805_bib23 article-title: Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans publication-title: PLoS One doi: 10.1371/journal.pone.0023710 – volume: 18 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib44 article-title: Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein publication-title: Virology Journal doi: 10.1186/s12985-021-01490-7 – volume: 12 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib46 article-title: A novel hamster model of SARS-CoV-2 respiratory infection using a pseudotyped virus publication-title: Scientific Reports – volume: 10 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib38 article-title: Ambulatory COVID-19 patients treated with lactoferrin as a supplementary antiviral agent: A preliminary study publication-title: Journal of Clinical Medicine doi: 10.3390/jcm10184276 – volume: 19 start-page: 2806 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib40 article-title: Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain publication-title: Computational and Structural Biotechnology Journal doi: 10.1016/j.csbj.2021.05.002 – volume: 603 start-page: 715 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib9 article-title: SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo publication-title: Nature doi: 10.1038/s41586-022-04479-6 – volume: 603 start-page: 706 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib27 article-title: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity publication-title: Nature doi: 10.1038/s41586-022-04474-x – volume: 66 start-page: 51 year: 2000 ident: 10.1016/j.idairyj.2023.105805_bib13 article-title: Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells publication-title: Virus Research doi: 10.1016/S0168-1702(99)00121-5 – volume: 10 start-page: 317 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib11 article-title: The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor publication-title: Emerging Microbes & Infections doi: 10.1080/22221751.2021.1888660 – volume: 83 start-page: 712 year: 2009 ident: 10.1016/j.idairyj.2023.105805_bib16 article-title: Protease-mediated entry via the endosome of human coronavirus 229E publication-title: Journal of Virology doi: 10.1128/JVI.01933-08 – volume: 96 start-page: 29 year: 2016 ident: 10.1016/j.idairyj.2023.105805_bib10 article-title: Coronavirus spike protein and tropism changes publication-title: Advances in Virus Research doi: 10.1016/bs.aivir.2016.08.004 – volume: 41 start-page: 2234 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib14 article-title: Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort publication-title: Vaccine doi: 10.1016/j.vaccine.2023.02.068 – volume: 1221 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib18 article-title: The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria publication-title: Frontiers in Immunology – volume: 86 start-page: 2269 year: 2005 ident: 10.1016/j.idairyj.2023.105805_bib5 article-title: Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein publication-title: Journal of General Virology doi: 10.1099/vir.0.80955-0 – volume: 57 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib1 article-title: The prospect of lactoferrin use as adjunctive agent in management of SARS-CoV-2 patients: A randomized pilot study publication-title: Medicina doi: 10.3390/medicina57080842 – volume: 14 year: 2022 ident: 10.1016/j.idairyj.2023.105805_bib31 article-title: Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants publication-title: mAbs doi: 10.1080/19420862.2022.2072455 – volume: 18 year: 2021 ident: 10.1016/j.idairyj.2023.105805_bib3 article-title: Lactoferrin as antiviral treatment in COVID-19 management: Preliminary evidence publication-title: International Journal of Environmental Research and Public Health doi: 10.3390/ijerph182010985 – volume: 120 year: 2023 ident: 10.1016/j.idairyj.2023.105805_bib25 article-title: Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants publication-title: Proceedings of the National Academy of Sciences of the United States of America – volume: 183 start-page: 739 year: 2020 ident: 10.1016/j.idairyj.2023.105805_bib48 article-title: Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant publication-title: Cell doi: 10.1016/j.cell.2020.09.032 |
| SSID | ssj0017039 |
| Score | 2.4305484 |
| Snippet | Severe acute respiratory coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The frequent appearance of variants requires adjunct strategies... |
| SourceID | proquest crossref |
| SourceType | Aggregation Database Enrichment Source Index Database |
| StartPage | 105805 |
| SubjectTerms | cattle COVID-19 infection glycoproteins humans lactoferrin mutants peptidyl-dipeptidase A proteinases Pseudoviridae serine Severe acute respiratory syndrome coronavirus 2 viruses |
| Title | Bovine lactoferrin suppresses the cathepsin-dependent pathway of SARS-CoV-2 entry in vitro |
| URI | https://www.proquest.com/docview/3153154095 |
| Volume | 148 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKcoED4imWl4zErXJJGydxjmW1qxXqLhJtUcUlsh1nm-6SVE0CKgd-OzN5NKlUaRcuVhvZbur5NP48M54h5IPQ9lBHIIHIw6TabqiYDH3JRMRxP7YtHeJB8eLSPZ_zzwtn0etNOlFLRa4G-vfBeyX_I1V4BnLFW7L_INndpPAAPoN8oQUJQ3snGX9Cc4Dp32DNnAhTLCb9rFiXoa2YuWGJMV3QrrM4YU212xxTqS5_ydKzPh1_nbKT9Bsb9csKI2j9-Bnnm7TLWfeNhqGMoV_39cqLM0pusSwTm8prCdJPm5D8eJu2Rm8TllR1lm7TJFXFTuMUWRWxWyTXu97TZfxD1v1hzmWcya6FYsQ7ForG1CiY69emxkbrctFfY5VhYTnsoC6vzAqrQVz-sdUAC73XA9rNq3HYX34JzuaTSTA7XczukfsjODRgPYvBn13AzxB0W515sXqb9j7Xx4M_ss9U9jfqkn3MHpNH9bGBjisMPCE9kzwlD8dXmzp1inlGvldooB000BYNFHBAD6CB1migaURbNNASDRRmKNHwnMzPTmcn56yunME0d5ycGdcAERbGksbWwreA8wLztJRGx7EQnHMFXyMkz8byIl97wDK152qDbnFl2S_IUZIm5iWhI1v5yh_KkbIFt6QUrpDD0PMcOTSh7VnHhDerFOg6rTxWN7kJmvjBVVAvboCLG1SLe0wGu2HrKq_KbQPeNyIIQAOiW0smJi2ywIZNGw4CINdXd-jzmjxoMfqGHOWbwrwFXpmrdyVc_gJKSns- |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bovine+lactoferrin+suppresses+the+cathepsin-dependent+pathway+of+SARS-CoV-2+entry+in+vitro&rft.jtitle=International+dairy+journal&rft.au=Kobayashi-Sakamoto%2C+Michiyo&rft.au=Maeda%2C+Toyonobu&rft.au=Yusa%2C+Junko&rft.au=Shimada%2C+Takahisa&rft.date=2024-01-01&rft.issn=0958-6946&rft.volume=148+p.105805-&rft_id=info:doi/10.1016%2Fj.idairyj.2023.105805&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0958-6946&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0958-6946&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0958-6946&client=summon |